Please ensure Javascript is enabled for purposes of website accessibility

Why Provention Bio Jumped Today

By Prosper Junior Bakiny - Updated Jun 15, 2020 at 7:33PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The company released positive data from a clinical trial for one of its pipeline candidates.

What happened?

Shares of Provention Bio (PRVB 1.28%) -- a clinical-stage biotech company -- jumped by 9.4% on Monday after the drugmaker reported positive data from a clinical trial for one of its lead pipeline candidates, teplizumab (PRV-031). 

So what

Provention Bio has big ambitions: The company is looking to develop a drug that can delay the onset of diabetes in patients who are at risk of developing the condition. In June 2019, Provention Bio announced positive results from a clinical trial for teplizumab. During the trial, a 14-day course of teplizumab delayed the onset and diagnosis of type 1 diabetes by a median of two years in at-risk patients. The data showed that only 43% of patients on teplizumab developed diabetes, compared to 72% in the placebo group.

Upward pointing arrows on a blackboard.

Image Source: Getty Images.

Today, Provention Bio announced additional data showing that teplizumab delayed the onset and diagnosis of type 1 diabetes by a median of three years, which is better than the two years' delay the company had previously reported. In April, Provention Bio initiated a rolling submission for its Biologic License Application (BLA) to the U.S. Food and Drug Administration (FDA) for teplizumab. The rolling submission allows the company to submit completed sections of its BLA for review, as opposed to submitting every completed section at once.

Now what

Provention Bio's teplizumab is a promising drug, and if it is approved, it could become a blockbuster product. Diabetes is a serious health condition that affects millions of Americans, and the diabetes market represents a multi-billion dollar opportunity. Given these factors, investors might want to keep an eye on this small-cap biotech stock

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Provention Bio, Inc. Stock Quote
Provention Bio, Inc.
PRVB
$3.96 (1.28%) $0.05

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
330%
 
S&P 500 Returns
115%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/22/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.